Immunomodulatory effects of linomide in animals immunized with immunopathogenic retinal antigens: Dissociation between different immune functions

Clinical and Experimental Immunology

Volumn 108, Issue 3, 1997, Pages 539-544

  Shirkey, B L ^a,b   Slavin, S ^c   Vistica, B P ^a   Podgor, M J ^a   Gery, I ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

autoimmune disease; immunomodulation; linomide; uveitis

Indexed keywords

ROQUINIMEX;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; UVEITIS; UVEORETINITIS;

EID: 0030904176     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.3681268.x     Document Type: Article

References (34)

1. Forrester JV. Uveitis: pathogenesis. Lancet 1991; 338:1498-501.
2. Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis. Fundamentals and clinical practice, 2nd edn. St Louis: Mosby, 1996.
3. Gery, I, Nussenblatt RB. Immunosuppressive drugs and therapy in ophthalmology. In: Sears ML, ed. Handbook of experimental pharmacology, Vol. 69. Berlin: Springer-Verlag, 1984:585-609.
4. Whitcup SM, Nussenblatt RB. Treatment of autoimmune uveitis. Ann NY Acad Sci 1993; 696:307-18.
5. Karussis DM, Lehmann D, Slavin S et al. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci USA 1993; 90:6400-4.
6. Karussis DM, Lehmann D, Slavin S et al. Inhibition of acute experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol 1993; 34:654-60.
7. Karussis DM, Lehmann D, Brenner T et al. Immunomodulation of experimental autoimmune myasthenia gravis with linomide. J Neuroimmunol 1994; 55:187-93.
8. Slavin S, Sidi H, Weiss L et al. Linomide, a new treatment for autoimmune diseases: the potential in type I diabetes. Diabetes/Metabolism Rev 1993; 9:311-5.
9. Gross DJ, Sidi H, Weiss L et al. Prevention of diabetes mellitus in non-obese diabetic mice by linomide, a novel immunomodulating drug. Diabetologia 1994; 37:1195-201.
10. Kalland T, Alm G, Stalhandske T. Augmentation of mouse natural killer cell activity by LS2616, a new immunomodulator. J Immunol 1985; 134:3956-61.
11. Stalhandske T, Kalland T. Effects of the novel immunomodulator LS2616 on the delayed-type hypersensitivity reaction to Bordetella pertussis in the rat. Immunopharmacology 1986; 11:87-92.
12. Kalland T, Maksimova A, Stalhandske T. Prophylaxis and treatment of experimental tumours with the immunomodulator LS2616. Int J Immunopharmacol 1985; 7:390.
13. Wanders A, Vogt P, Karlsson-Parra A et al. Evidence that LS2616 (linomide) causes acute rejection of rat allografts protected by cyclosporine but not of long-term allografts. Transplantation 1991; 52: 234-8.
14. Kleinau S, Larsson P, Bjork J et al. Linomide, a new immunomodulatory drug, shows different effects on homologous versus heterologous collagen-induced arthritis in rats. Clin Exp Immunol 1989; 78:138-42.
15. Gery I, Mochizuki M, Nussenblatt RB. Retinal specific antigens and immunopathogenic processes they provoke. Prog Retinal Res 1986; 5:75-109.
16. Ichikawa T, Tagachi O, Takahashi T et al. Spontaneous development of autoimmune uveoretinitis in nude mice following reconstitution with embryonic rat thymus. Clin Exp Immunol 1991; 86: 112-7.
17. Greenwood 3, Howes R, Lightman S. The blood-retinal barrier in experimental autoimmune uveoretinitis. Leukocyte interactions and functional damage. Lab Invest 1994; 70:39-52.
18. Gery I, Streilein JW. Autoimmunity in the eye and its regulation. Curr Opin Immunol 1994; 6:938-45.
19. Dorey C, Cozette J, Faure JP. A simple and rapid method for isolation of retinal S antigen. Ophthalmic Res 1982; 14:249-55.
20. McAllister CG, Wiggert B, Chader GJ et al. Uveitogenic potential of lymphocytes sensitized to interphotoreceptor retinoid-binding protein. J Immunol 1987; 138:1416-20.
21. Fox GM, Kuwabara T, Wiggert B et al. Experimental autoimmune uveoretinitis (EAU) induced by retinal interphotoreceptor retinoid-binding protein (IRBP): differences between EAU induced by IRBP and by S-antigen. Clin Immunol Immunopathol 1987; 43:256-64.
22. Caspi RR, Roberge FG, Chan CC et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 1988; 140: 1490-5.
23. Mochizuki M, Nussenblatt RB, Kuwabara T, Gery I. Effects of cyclosporine and other immunosuppressive drugs on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci 1985; 26:226-32.
24. Kotake S, deSmet MD, Wiggert B et al. Analysis of the pivotal residues of the immunodominant and highly uveitogenic determinant of interphotoreceptor retinoid-binding protein. J Immunol 1991; 146:2995-3001.
25. Lehman PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992; 358:155-7.
26. Caspi RR, Roberge FG, McAllister C et al. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol 1986; 136:928-33.
27. Mochizuki M, Nussenblatt RB, Kuwabara T, Gery I. Effects of cyclosporine on the efferent limb of the immune response. Transplant Proc 1983; 15 (Suppl. 1):2364-6.
28. Chanaud NP III, Vistica BP, Eugui E et al. Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Exp Eye Res 1995; 61:429-34.
29. Karussis DM, Meiner Z, Lehmann D et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double blind-placebo controlled pilot study with monthly MRI evaluation. Neurology 1995; 45 (Suppl.):A417.
30. Swain SL, Croft M, Dubey C et al. From naive to memory T cells. Immunol Rev 1996; 150:143-67.
31. Richert JW, Driscoll BF, Kies MW et al. Adoptive transfer of experimental allergic encephalomyelitis. Incubation of rat spleen cells with specific antigen. J Immunol 1979; 122:494-6.
32. 4 integrin by CD4 T cells is required for their entry into drain parenchyma. J Exp Med 1993; 177:57-68.
33. Weinberg AD, English M, Swain SL. Distinct regulation of lymphokine production is found in fresh versus in vitro primed murine helper T cells. J Immunol 1990; 144:1800-7.
34. h1 cytokine gene expression. Int Immunol 1996; 8:1603-7.